Neoadjuvant systemic therapy for pleural mesothelioma patients: a systematic review
Neoadjuvant systemic therapy with platinum‑based chemotherapy is common in pleural mesothelioma, yet its ability to improve survival compared with chemotherapy alone remains uncertain, and the role of immunotherapy is still under investigation.
Pleural mesothelioma is an aggressive malignancy with a poor prognosis. The role of surgery in its management remains controversial, with ongoing debate regarding the definition of resectable disease. Neoadjuvant therapy aims to reduce tumor burden. This systematic review evaluates prospective neoadjuvant trials in pleural mesothelioma to identify subgroups that may benefit from this approach. Sixteen trials were found: 861/1,184 patients (72.7%) were male, median age ranged between 57‑69 years. Neoadjuvant chemotherapy was used in 15 trials and immunotherapy in one trial. Surgery was performed in 61.8% of patients, with extrapleural pneumonectomy (EPP) being the predominant approach. Median overall survival in single‑arm trials was 17.4 months, n=523 for the intention‑to‑treat population and 21.4 months, n=345 for the surgery population. The phase‑III trial (MARS‑2) comparing neoadjuvant chemotherapy plus extended pleurectomy decortication versus chemotherapy alone found a shorter median survival in the surgery and chemotherapy group (19.3 months vs. 24.8 months, p=0.01). This review shows that the predominant neoadjuvant approach consists of platinum doublet chemotherapy, but the role of immunotherapy is being explored. Additional randomized trials are needed to determine the optimal neoadjuvant strategy and patient subgroups most likely to benefit.
Pleural mesothelioma is an aggressive cancer with a poor prognosis, and the role of surgery within multimodality therapy remains controversial. Evidence that neoadjuvant therapy may or may not improve survival is critical for guiding clinical decision‑making.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Moving Beyond Morphology: Toward a Morpho‑Molecular Classification of Pleural Mesothelioma
- Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System
- Systemic Treatments for Unresectable Pleural Mesothelioma: A Review of the Literature
- Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma
- Tumor Treating Fields (TTFields) for Pleural Mesothelioma